- Home
- TSHA vs ADAMZ Comparison
TSHA vs ADAMZ Comparison
Compare TSHA & ADAMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- ADAMZ
- Stock Information
- Founded
- TSHA 2019
- ADAMZ N/A
- Country
- TSHA United States
- ADAMZ United States
- Employees
- TSHA N/A
- ADAMZ N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- ADAMZ Real Estate Investment Trusts
- Sector
- TSHA Health Care
- ADAMZ Real Estate
- Exchange
- TSHA Nasdaq
- ADAMZ Nasdaq
- Market Cap
- TSHA 1.4B
- ADAMZ 1.6B
- IPO Year
- TSHA 2020
- ADAMZ N/A
- Fundamental
- Price
- TSHA $3.84
- ADAMZ $18.68
- Analyst Decision
- TSHA Strong Buy
- ADAMZ
- Analyst Count
- TSHA 9
- ADAMZ 0
- Target Price
- TSHA $10.22
- ADAMZ N/A
- AVG Volume (30 Days)
- TSHA 4.1M
- ADAMZ N/A
- Earning Date
- TSHA 11-04-2025
- ADAMZ N/A
- Dividend Yield
- TSHA N/A
- ADAMZ N/A
- EPS Growth
- TSHA N/A
- ADAMZ N/A
- EPS
- TSHA N/A
- ADAMZ N/A
- Revenue
- TSHA $6,310,000.00
- ADAMZ N/A
- Revenue This Year
- TSHA N/A
- ADAMZ N/A
- Revenue Next Year
- TSHA N/A
- ADAMZ N/A
- P/E Ratio
- TSHA N/A
- ADAMZ N/A
- Revenue Growth
- TSHA N/A
- ADAMZ N/A
- 52 Week Low
- TSHA $1.05
- ADAMZ N/A
- 52 Week High
- TSHA $5.51
- ADAMZ N/A
- Technical
- Relative Strength Index (RSI)
- TSHA 37.78
- ADAMZ N/A
- Support Level
- TSHA $3.89
- ADAMZ N/A
- Resistance Level
- TSHA $4.55
- ADAMZ N/A
- Average True Range (ATR)
- TSHA 0.39
- ADAMZ 0.00
- MACD
- TSHA -0.19
- ADAMZ 0.00
- Stochastic Oscillator
- TSHA 8.99
- ADAMZ 0.00
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.